Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain.
Although Candida albicans (CA) is the most common cause of Candida bloodstream infections (BSIs), recent studies have observed an increasing percentage of candidaemias caused by non-albicans Candida species (NAC). In the present study, we attempted to identify the predictors of candidaemia due to NAC compared to CA. We analyzed data from an active population-based surveillance in Barcelona (Spain) from January 2002 to December 2003. Factors associated with NAC fungaemia were determined by multivariate analysis. A total of 339 episodes of Candida BSI, in 336 patients (median age 63 years, interquartile range: 41-72 years), were included. CA was the most commonly isolated (52%), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8.6%), Candida krusei (3.4%) and other NAC spp. (3%).Overall, 48% of cases were due to NAC spp. Multivariate logistic regression analysis identified factors associated with a risk of BSI due to NAC spp.: having received a haematologic transplant (OR 10.8; 95% CI 1.31-90.01; p 0.027), previous fluconazole exposure (OR 4.47; 95% CI 2.12-9.43; p <0.001) and neonatal age (OR 4.42; 95% CI 1.63-12.04; p 0.004). Conversely, previous CA colonization (OR 0.33; 95% CI 0.19-0.57; p 0.001) and previous antibiotic use (OR 0.42; 95% CI 0.21-0.85; p 0.017) were associated with CA fungaemia compared to NAC. In conclusion, NAC candidaemia comprised 48% of cases in our series. Predictors of NAC include having received a haematologic transplant, neonatal age and previous fluconazole use.
Rodríguez
D
D
Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. dolorodriguez@vhebron.net
Almirante
B
B
Cuenca-Estrella
M
M
Rodríguez-Tudela
J L
JL
Mensa
J
J
Ayats
J
J
Sanchez
F
F
Pahissa
A
A
D000328:Adult; D000367:Age Factors; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage; D002175:Candida / Q000145:classification*; D058387:Candidemia / Q000453:epidemiology* / Q000382:microbiology*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D012044:Regression Analysis; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D065227:Transfusion Reaction
D000935:Antifungal Agents; D015725:Fluconazole